GlobeNewswire·Nov 2, 2026, 7:05 PM ET

UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study

Alamar Biosciences & Nightingale Health launched the UK Biobank vanguard study (UKB-PRISM) to measure blood-based protein biomarkers for neurodegenerative diseases.
The study will utilize Alamar's NULISA platform to analyze hundreds of circulating protein biomarkers in 80,000 blood samples from UK Biobank participants.
Testing will be conducted in Nightingale Health's laboratories to detect low-abundance proteins at a sensitivity previously unachievable at scale.
Findings will create one of the world's largest open-access resources for identifying early molecular indicators of brain health decades before diagnosis.
The project aims to understand Alzheimer's & Parkinson's disease as overlapping conditions with shared biological roots by measuring signals before symptoms emerge.
Funding is provided by The Michael J. Fox Foundation, Alzheimer's Research UK, & LifeArc, with completion expected by the end of 2027.
Results will be integrated with existing UK Biobank imaging, genetic, metabolomic, & lifestyle data to enhance disease research & early detection capabilities.
Upon completion, the full dataset will be made available to approved researchers worldwide via the UK Biobank Research Analysis Platform.